The Acute & Maintenance Treatment of Asthma via Aerosolized Medications

Similar documents
Biologic Agents in the treatment of Severe Asthma

Improving Outcomes in the Management & Treatment of Asthma. April 21, Spring Managed Care Forum

GINA. At-A-Glance Asthma Management Reference. for adults, adolescents and children 6 11 years. Updated 2017

Asthma Upate 2018: What s New Since the 2007 Asthma Guidelines of NAEPP?

Asthma Management in Pregnancy HEATHER HOWE, MD UNIVERSITY OF UTAH PULMONARY DIVISION

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

12/18/2017. Disclosures. Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing

Brooke L. Gildon, Pharm.D., BCPS, BCPPS, AE C

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing

Asthma Update A/Prof. John Abisheganaden. Senior Consultant, Dept Of Respiratory & Crit Care Medicine Tan Tock Seng Hospital

Treatment Responses. Ronald Dahl, Aarhus University Hospital, Denmark

Robert Kruklitis, MD, PhD Chief, Pulmonary Medicine Lehigh Valley Health Network

MEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 07/05/18 SECTION: DRUGS LAST REVIEW DATE: LAST CRITERIA REVISION DATE: ARCHIVE DATE:

LONG-ACTING BETA AGONISTS

Asma e BPCO: le strategie terapeutiche

Amanda Hess, MMS, PA-C President-Elect, AAPA-AAI Arizona Asthma and Allergy Institute Scottsdale, AZ

Cynthia S. Kelly, M.D. Professor of Pediatrics Eastern Virginia Medical School Division Director Allergy Children s Hospital of The King s Daughters

#1 cause of school absenteeism in children 13 million missed days annually

Do We Need Biologics in Pediatric Asthma Management?

benralizumab (Fasenra )

Asthma Therapy 2017 JOSHUA S. JACOBS, M.D.

Learning the Asthma Guidelines by Case Studies

Drug Prior Authorization Guideline NUCALA (mepolizumab)

Difficult Asthma Assessment: A systematic approach

Global Initiative for Asthma (GINA) What s new in GINA 2015?

reslizumab (Cinqair )

Defining COPD. Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist

Cinqair (reslizumab injection for intravenous use)

Cigna Drug and Biologic Coverage Policy

Emily DiMango, MD Asthma II

Global Initiative for Asthma (GINA) What s new in GINA 2016?

Kirthi Gunasekera MD Respiratory Physician National Hospital of Sri Lanka Colombo,

Bronchial asthma. MUDr. Mojmír Račanský Odd. Alergologie a klinické imunologie FNOL Ústav Imunologie LF UPOL

FASENRA (benralizumab)

The Latest Medications A Pharmacological Update for RTs

Traiter l asthme sévère par le phénotype. Dr. Alain Michils CUB-Hôpital Erasme

Foundations of Pharmacology

Using Inhaled Corticosteroids as Needed for Asthma: giving patients relief or leaving them breathless?

Turning Science into Real Life Roflumilast in Clinical Practice. Roland Buhl Pulmonary Department Mainz University Hospital

Question I was one of the first dry power devices available in the US Flovent, Serevent and Advair are all available in this device

Asthma training. Mike Levin Division of Asthma and Allergy Red Cross Hospital

Asthma for Primary Care: Assessment, Control, and Long-Term Management

UPDATE ON ASTHMA MEDICATIONS INCLUDING BIOLOGICS FOR SEVERE PERSISTENT ASTHMA JOAN O LEAR FNP AE- C KENWOOD ALLERGY AND ASTHMA CENTER

Supplementary Medications during asthma attack. Prof. Dr Finn Rasmussen PhD. DrMedSc. Near East University Hospital North Cyprus

Asthma Pharmacotherapy 2017: Stepwise Approach to Managing Asthma

Biologics in asthma Are we turning the corner? Roland Buhl Pulmonary Department Mainz University Hospital

COPD: A Renewed Focus. Disclosures

Exercise-Induced Bronchospasm. Michael A Lucia, MD, FCCP Asst Clinical Professor, UNR School of Medicine Sierra Pulmonary & Sleep Institute

New TLD Indication: Asthma RELIEF-1 Study. Nick ten Hacken, MD Study Co-Principal Investigator

Meeting the Challenges of Asthma

Asthma/COPD Update with Inhaler Workshop

Objectives. Asthma in Primary Care. Definition. Epidemiology. Pathophysiology

Long Term Care Formulary RS -29

Dual-Controller Asthma Therapy: Rationale and Clinical Benefits

Who can get most benefit

Xolair (Omalizumab) Drug Prior Authorization Protocol (Medical Benefit & Part B Benefit)

Asthma Update I have no professional or personal financial conflicts of interest to disclose.

Asthma Update Jennifer W. McCallister, MD, FACP, FCCP

Step up if needed (first, check adherence, environmental control and comorbid conditions) Patients ASSESS CONTROL. Step down if possible

Searching for Targets to Control Asthma

COPD and Asthma Update. April 29 th, 2017 Rachel M Taliercio, DO Staff, Respiratory Institute

Omalizumab (Xolair) NHLBI normal ranges by age for FEV 1/FVC 8-19 years of age 85%; years of age 80%;

MANAGING ASTHMA. Nancy Davis, RRT, AE-C

Global Initiative for Asthma (GINA) What s new in GINA 2017?

Is reslizumab effective in improving quality of life and asthma control in adolescent and adult patients with poorly controlled eosinophilic asthma?

Asthma Description. Asthma is a disease that affects the lungs defined as a chronic inflammatory disorder of the airways.

New Therapies for Asthma

II: Moderate Worsening airflow limitations Dyspnea on exertion, cough, and sputum production; patient usually seeks medical

Treatment Options for Complicated/Severe Asthma. Henry J. Kanarek, MD Kanarek Allergy Asthma Immunology

Asthma/COPD. Asthma synopsis. chronic inflammation of bronchial airways bronchi lining bronchi muscles mucus

PFT s / 2017 Pulmonary Update. Eric S. Papierniak, DO University of Florida NF/SG VHA

Nucala (mepolizumab injection for subcutaneous use)

The methodology behind GINA and EPR-3 medication recommendations: Stepwise treatment in asthma

The Pharmacist s Role in Managing Severe Asthma. This activity is supported by an educational grant from Genentech. Educational Objectives

Management of Severe Asthma Including Biologics and Bronchial Thermoplasty. Karen L. Gregory, DNP, APRN, CNS, RRT, AE-C, FAARC

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Asthma. Rachel Miller, MD, FAAAAI Director Allergy and Immunology New York Presbyterian Hospital. Figure 1 Asthma Prevalence,

Management of Acute Asthma Exacerbations in Children 2012 Update. Sharon Kling Dept Paediatrics & Child Health University of Stellenbosch

4/3/2018 BRANDY BURGESS, APRN-CNS, MSN-RN APRIL 12-14, 2018

This is the publisher s version. This version is defined in the NISO recommended practice RP

Asthma in Pediatric Patients. DanThuy Dao, D.O., FAAP. Disclosures. None

Greater Manchester Asthma Management Plan 2018 Inhaler therapy options for adult patients (18 and over) with asthma

Clinical Implications of Asthma Phenotypes. Michael Schatz, MD, MS Department of Allergy

Add on therapy in asthma. Local experience in context J Paul Dilworth, Nicola Marks, Lauren Geddes

Alberta Childhood Asthma Pathway for Primary Care

Asthma in Pregnancy. Asthma. Chronic Airway Inflammation. Objective Measures of Airflow. Peak exp. flow rate (PEFR)

(Asthma) Diagnosis, monitoring and chronic asthma management

Asthma Pathophysiology and Treatment. John R. Holcomb, M.D.

Asthma Treatment Update: 2018

Breakfast Session Prof Neil Barnes Professor of Respiratory Medicine London Chest Hospital & The Royal London Hospital United Kingdom

Drug Class Monograph

Medicine Dr. Kawa Lecture 4 - Treatment of asthma :

Policy Effective 4/1/2018

Interventions to improve adherence to inhaled steroids for asthma. Respiratory department

XOLAIR (omalizumab) Prior Authorization

Step-down approach in chronic stable asthma: A comparison of reducing dose Inhaled Formoterol/ Budesonide with maintaining Inhaled Budesonide.

Assessing Primary Care Physician s Beliefs and Attitudes of Asthma Exacerbation Treatment and Follow-Up

Nancy Davis, RRT, AE-C

December 7, 2010 Future Use of Biologics in Allergy and Asthma

Transcription:

The Acute & Maintenance Treatment of Asthma via Aerosolized Medications Douglas S. Gardenhire, EdD, RRT-NPS, FAARC Associate Professor and Chairman Department of Respiratory Therapy

Objectives Define Asthma. Determine aerosolized agents used to treat acute asthma. Determine aerosolized agents used to maintain asthma control. Utilize guidelines to treat acute asthma. Utilize guidelines to maintain asthma control.

Definition of Asthma Asthma is a heterogeneous disease, usually characterized by chronic airway inflammation. It is defined by the history of respiratory symptoms such as wheeze, shortness of breath, chest tightness and cough that vary over time and in intensity, together with variable expiratory airflow limitation. GINA, 2016

Question 1 Is Racemic Epinephrine or Epinephrine available over-the counter to treat asthma? Yes No

Short-Acting b Adrenergic Agents Ultra Short-acting Epinephrine Racemic Epinephrine (SABA)

Question 2 Does Step 1 in GINA and NAEPP guidelines recommend a SABA for the treatment of asthma? Yes No

Short-Acting b Adrenergic Agents Short-acting Albuterol Levalbuterol (SABA)

Use in Asthma a agonists are not routinely used for treatment of asthma Epi v. Terbutabline, No difference detected (n=38) Adoun, M et al. J Crit Care, Vol 19, No 2 (June), 2004: pp 99-102 SABA main bronchodilator of choice (NAEPP, 2007) Use as needed Regularly scheduled use is not recommended Use of at least 1 week decreases tolerance, associated with poor disease control. Salpeter, Ann Intern Med. 2004;140:802-813

Downregulation From Gardenhire, DS Rau s Respiratory Care Pharmacology, 2016 Mosby, St. Louis, MO

GINA <5 years old

GINA 6-11 years old

GINA 12 years old- Adult

Question 3 Corticosteroids assist beta agonists in working better? Yes No

Upregulation Corticosteroids Increase the proportion of beta receptors on the cell membrane Increase affinity of beta receptors Inhibit the release of inflammatory mediators

Corticosteroids From Gardenhire, DS Rau s Respiratory Care Pharmacology, 2016 Mosby, St. Louis, MO

GINA <5 years old

GINA 6-11 years old

GINA 12 years old- Adult

Long-Acting b Adrenergic Agents (LABA) Salmeterol DPI 50mcg/actuation 4 years old +

Black Box Warning

Problems with Long-term Bronchodilators SMART Chest 2006 Led to regulatory warning Salapeter et al. Annu Intern Med 2006 Long-acting Beta2 agonists increases the risk of asthma hospitalizations and deaths compared to placebo Nelson et al. Chest 2006 Increase in death rate while using salmeterol Mann et al. Chest 2003 Increased exacerbations in patients receiving Formoterol

Use in Asthma Addition of Salmeterol or Formoterol for uncontrolled asthma when not controlled on low/med-dose ICS Reduce exacerbations/use of SABA (Greenstone et al. Cochrane Database Syst Rev 2005) Should not be used as monotherapy Daily use should not exceed 100 mcg salmeterol 24 mcg formoterol Consideration for increasing ICS before adding LABA (NAEPP, 2007)

GINA <5 years old

GINA 6-11 years old

GINA 12 years old- Adult

Fixed Drug Combinations From Gardenhire, DS Rau s Respiratory Care Pharmacology, 2016 Mosby, St. Louis, MO

Question 4 As a respiratory care practitioner do you see the use of anticholinergics such as ipratropium bromide used regularly in your daily practice? Yes No

Question 5 Are anticholinergics regularly used in the treatment of asthma? Yes No

Anticholinergic Agents Ipratropium Bromide Tiotropium Bromide 1.25 mcg via Respimat

Complementary Effect From Gardenhire, DS Rau s Respiratory Care Pharmacology, 2016, Mosby, St. Louis, MO

GINA 12 years old- Adult

Use in Asthma Not superior to beta agonists (NAEPP, 2007; GINA, 2016) Asthmatic patients treated with Beta blockers Alternative to theophylline Acute, severe exacerbations not responding to beta agonists (Weber. Ann Allergy, 1990)

Cont. Ipratropium added lowered hospitalization rate of children with acute moderate to severe asthma (Qureshi et al. N Engl J Med 1998) Adding multiple doses of ipratropium to beta agonist Improved lung function Avoided hospital admission (1 in 11) (Plotnick & Ducharme, Br Med J 1998)

Cont. Add-on tiotropium by mist inhaler improves lung function and increases the time to severe exacerbation (Rodrigo GJ et al. Chest 2015;147:388-96) In patients selected for uncontrolled symptoms and persistent airflow limitation despite moderate-high dose ICS and LABA, add-on tiotropium, improved lung function and increased time to first exacerbation. (Kerstjens HA et al. Engl J Med 2012;367:1198-207)

Xanthines Theophylline Aminophylline Oxtriphylline Dyphylline

Use in asthma Small therapeutic index Less asthma control than ICS (Dahl et al. Respir Med 2002) Non-preferred alternative, cost consideration for inhaled meds (NAEPP, 2007, GINA 2016) IV aminophylline and theophylline should not be used in the management of exacerbations (Nair P et al. Cochrane Database Syst Rev 2012;12:CD002742) Theophylline does not improve outcomes compared with SABA alone. Nair P et al.cochrane Database Syst Rev 2012;12:CD002742)

Mast Cell Stabilizer and Leukotriene Modifiers From Gardenhire, DS Rau s Respiratory Care Pharmacology, 2016 Mosby, St. Louis, MO

Use in asthma Cromolyn has favorable safety profile but low efficacy (Guevara JP et al. Cochrane Database Syst Rev 2006:CD003558) Leukotriene receptor antagonists (LTRA) are less effective than ICS (Chauhan BF et al. Cochrane Database Syst Rev 2012;5:CD002314) Limited evidence for LTRAs in acute asthma. Small studies have demonstrated improvement (Ramsay CF et al. Thorax 2011;66:7-11) Regular treatment with LTRA in young children modestly reduced symptoms and need for oral corticosteroids (Bisgaard H et al. Am J Respir Crit Care Med 2005;171:315-22)

Monoclonal Antibodies Omalizumab (Xolair) Anti-IgE 12 years and older Positive skin test to aeroallergen Mepolizumab (Nucala) Interleukin-5 antagonist 12years and older Eosinophilic phenotype Reslizumab (Cinqair) Interleukin-5 antagonist 18 years and older Eosinophilic phenotype

GINA <5 years old

GINA 6-11 years old

GINA 12 years old- Adult

Treatment of Exacerbation

GINA 2016

GINA 2016

Summary SABA first line agents Corticosteroids first agent to consider in uncontrolled asthma LABA are effective, work best with corticosteroids Xanthines have unwanted side effects Cormolyn and Antileukotriens are safe, but not always effective Ipratropium can be considered but not routine Tiotropium add-on treatment only Each patient is different, EDUCATE!

Questions, Comments, Happy Thoughts? dgardenhire@gsu.edu Twitter @RTPharmacology